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Background: Alzheimer’s disease (AD) pathology occurs in part as the result of excessive production of β-amyloid
(Aβ). Metabotropic glutamate receptor 5 (mGluR5) is now considered a receptor for Aβ and consequently contributes
to pathogenic Aβ signaling in AD.
Results: Genetic deletion of mGluR5 rescues the spatial learning deficits observed in APPswe/PS1ΔE9 AD mice.
Moreover, both Aβ oligomer formation and Aβ plaque number are reduced in APPswe/PS1ΔE9 mice lacking mGluR5
expression. In addition to the observed increase in Aβ oligomers and plaques in APPswe/PS1ΔE9 mice, we found that
both mTOR phosphorylation and fragile X mental retardation protein (FMRP) expression were increased in these
mice. Genetic deletion of mGluR5 reduced Aβ oligomers, plaques, mTOR phosphorylation and FMRP expression
in APPswe/PS1ΔE9 mice.
Conclusions: Thus, we propose that Aβ activation of mGluR5 appears to initiate a positive feedback loop
resulting in increased Aβ formation and AD pathology in APPswe/PS1ΔE9 mice via mechanism that is regulated
by FMRP.
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Alzheimer’s disease (AD) is the most prevalent neurode-
generative illness in older adults and has a characteristic
neuropathology that includes plaques comprised of β
amyloid (Aβ) and tangles of hyperphosphorylated tau
[1,2]. Aβ42 is formed by the sequential proteolytic cleav-
age of the amyloid precursor protein (APP), by β- and
γ-secretases, via what is referred to as the amyloido-
genic pathway and are commonly found as soluble
oligomers and fibrillar plaques [3]. A considerable body
of evidence suggests that soluble Aβ oligomers are the
predominant neurotoxic species of Aβ, with the Aβ42
fragment being found to be particularly potent [4,5]. Aβ42
oligomers exert their toxic effects by binding to neuronal
synapses, causing disruption to normal synaptic signaling,
which often leads to neuronal death [6,7]. However, the* Correspondence: ferguson@robarts.ca
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controversial.
Glutamate is the primary excitatory neurotransmitter
in the brain and activates both ionotropic glutamate re-
ceptors and G protein-coupled metabotropic glutamate
receptors (mGluRs) [8]. Alterations in normal mGluR5
signaling is associated with the autism spectrum disorder,
fragile X syndrome, and a number of neurodegenerative
diseases that include: Huntington’s disease, Parkinson’s
disease and AD [9-17]. mGluR5 couples to the heterotri-
meric G protein Gαq/11, which activates phospholipase C
resulting in increased inositol-1,4,5-triphosphate forma-
tion and the release of Ca2+ from intracellular stores
[3,12]. Recently, it has been demonstrated that mGluR5
also serves as the receptor for both cellular prion protein
(PrPc) and Aβ42, which activate mGluR5 to release Ca2+
from intracellular stores [17-20].
It is now well recognized that mGluR5 regulates the
activity of the fragile X mental retardation protein
(FMRP), a RNA binding protein that functions to repress
protein synthesis at synapses [21-25]. The activation ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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APP and FMRP expression [16,26]. This increase in APP
expression results in the augmented secretion of both
toxic Aβ42 oligomers and the non-toxic soluble APP
(sAPPα) fragment [16,24]. Thus, although the precise
mechanism remains unclear, this data suggests that, in
addition to an established role in fragile X syndrome,
mGluR5 and FMRP likely contribute directly to AD
pathogenesis [16,27].
In the present study, we assess the role for mGluR5 in AD
pathogenesis by crossing the APPswe/PS1ΔE9 double trans-
genic mouse model of AD with mGluR5 null mice. We find
that the genetic deletion of mGluR5 reverses the spatial
memory deficits observed in APPswe/PS1ΔE9 mice. FMRP
protein expression is also increased APPswe/PS1ΔE9 mice
and following the genetic deletion of mGluR5 FMRP
expression is reduced to wild-type levels and results in
the significant decrease of aggregated β-amyloid levels
and β-amyloid plaque number in APPswe/PS1ΔE9 mice.
These studies provide evidence for a central role of
mGluR5 in AD pathogenic mechanisms that are associ-
ated with increased Aβ.
Results
Genetic deletion of mGluR5 rescues spatial memory
deficits in APPswe/PS1ΔE9 mice
Given the potential role for mGluR5 as a receptor for Aβ
[17-20], we crossed mGluR5 knockout mice with APPswe/
PS1ΔE9 mice. The double transgenic APPswe/PS1ΔE9
mice were previously found to exhibit impaired cogni-
tive function as early as 7 months of age [28-30]. There-
fore, our initial studies tested whether the genetic deletion
of mGluR5 improved spatial memory deficits in APPswe/
PS1ΔE9 mice at both nine and twelve months of age in
the Morris Water Maze test. Mice were exposed to the
maze for sixteen 90 s trials over 4 days during the acquisi-
tion phase (4 trials per day), followed by a 60 s probe trial
on day 5. The swimming ability for all four mouse geno-
types was consistent and indistinguishable at both nine
and twelve months of age (Figure 1A and B). However, re-
peated measures analysis of variance indicated that spatial
learning of 9 month old mice (Figure 1C and E), as mea-
sured by either the escape latency or swim path length,
varied as a function of the genotype, F(3,41) = 4.83, and
11.20, p’s < 0.01, respectively. Precisely the same profile
was apparent in mice at 12 months of age (Figure 1D
and F). Follow-up Bonferonni corrected t tests con-
firmed that performance of APPswe/PS1ΔE9 mice was
significantly impaired when compared to wild-type and
mGluR5−/− mice. However, the genetic deletion of mGluR5
rescued the spatial learning deficit in APPswe/PS1ΔE9 mice
at both ages. The genotype differences were consistent and
the interaction between Strain and Days did not reach statis-
tical significance.During the probe trial on day 5, in which the platform
was removed, the genotypes varied appreciably with re-
spect to the time spent in the target quadrant, F(3,41) =
20.62 and 21.66, p ‘s < 0.001 for mice tested at 9 and
12 months respectively. The follow-up tests confirmed
that APPswe/PS1ΔE9 mice spent less time in the target
quadrant relative to all other genotypes at either nine or
twelve months of age, but that the loss of mGluR5 ex-
pression improved APPswe/PS1ΔE9 mouse behaviour
(Figure 1G and H). The time that the mice spent in each
quadrant of the pool is shown in Additional file 1: Figure S1.
Thus, our observation that the genetic deletion of mGluR5
resulted in significantly improved spatial temporal memory
in APPswe/PS1ΔE9 mice was consistent with a recent re-
port that pharmacological blockade of mGluR5 improved
behavioural deficits in APPswe/PS1ΔE9 mice [17].
Effect of APPswe/PS1ΔE9 mutation on the locomotor,
anxiety and exploratory behavioural phenotypes of
mGluR5−/− mice
We previously showed that mGluR5−/− mice exhibit in-
creased locomotor activity that is reversed in the Q111
knock-in mutant huntingtin genetic background [12].
Moreover, APPswe/PS1ΔE9 mice were previously shown
to exhibit impaired exploratory behavior [28,29]. There-
fore, we wanted to ascertain that double transgenic ex-
pression of APPswe and PS1ΔE9 does not alter changes
in the locomotor (distance traveled), anxiety (centre time)
and exploratory (number of rearing events) behaviours in-
duced by mGluR5 deletion in twelve month old wild-type
and APPswe/PS1ΔE9 mice lacking mGluR5 expression
over a 2 h period in an open field arena. We found no dif-
ferences in the locomotor, centre time and exploratory be-
haviours of APPswe/PS1ΔE9 mice when compared to wild
type controls (Figure 2A-C). However, the genetic deletion
of mGluR5 resulted in locomotor hyperactivity, reduced
centre time in the open field, as well as increased explora-
tory behaviours in both APPswe/PS1ΔE9 mice and wild
type controls (Figure 2A-C). However, we did not find
a statistically significant increase in anxiety behaviour
in mGluR5 knockout mice in the elevated plus maze
(Figure 2D and E). Thus, double transgenic expression
of APPswe and PS1ΔE9 does not alter the changes in
locomotor, anxiety and exploratory behaviour that occur
as the consequence of mGluR5 deletion.
Genetic deletion of mGluR5 reduces Aβ in APPswe/PS1ΔE9
mice
Given that mGluR5 deletion improved cognition, we sought
to examine the effect on Aβ production and deposition. The
deposition of Aβ in APPswe/PS1ΔE9 mice occurs as early as
3 months of age [29-31]. Therefore, to assess the role of
mGluR5 on Aβ oligomer load, whole brains from 12 month
old mice were analyzed for Aβ oligomers using a sandwich
Figure 1 Genetic deletion of mGluR5 rescues spatial memory deficits in APPswe/PS1ΔE9 mice at 9 and 12 months of age. Shown are the swim
speeds at (A) 9 and (B) 12 months of age, escape latencies, at (C) 9 and (D) 12 months of age, and path lengths (E) at 9 and (F) 12 months of age for
wild-type (wt) (n = 16), APPswe/PSΔE9 (APPswe) (n = 11), mGluR5−/− (n = 14), and APPswe/mGluR5−/− (n = 14) mice recorded during the acquisition
phase in the Morris Water Maze test for spatial learning. Shown is the time that wt, APPswe, mGluR5−/−, and APPswe/ mGluR5−/− mice spent in the
target quadrant during the probe trial at (G) 9 and (H) 12 months of age. Data represent the mean ± SEM. Statistically significant * (p < 0.01)
and ** (p < 0.001) differences between mice groups when compared to wild-type mice. Statistical significance was assessed by repeated
measures ANOVA.
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mers in APPswe/PS1ΔE9 mice when compared to wild-type
controls, this increase in Aβ oligomers in APPswe/PS1ΔE9
mice was reduced to 1.2 ± 0.2 fold following the genetic de-
letion of mGluR5 (Figure 3A). This represented a 41 ± 6%
reduction in Aβ oligomers in APPswe/PS1ΔE9 mice lacking
mGluR5 expression when compared to APPswe/PS1ΔE9mice that express mGluR5. We also examined whether the
number of Aβ plaques were altered in APPswe/PS1ΔE9
mice lacking mGluR5 to rule out the possibility that Aβ olig-
omers were simply being converted more efficiently to pla-
ques to reduce cognitive decline. When quantified we found
that Aβ plaque number was also reduced in the cortex and
hippocampus of coronal brain slices, with the Aβ plaque
Figure 2 Genetic deletion of mGluR5 increases locomotor, anxiety and explorative behaviours in wild-type and APPswe/PS1ΔE9 mice
at 12 months of age. Graphs show (A) the total distance traveled, (B) the time spent in the centre quadrant of the open field and (C) number
of rearings for wild-type (wt) and APPswe/PS1ΔE9 (APPswe) mice on either mGluR5+/+ or mGluR5−/− genetic backgrounds. (D) Show is the total
distance traveled in the elevated plus maze. (E) Shown is the percentage of time spent in the open arm of the elevated plus maze. The number
of animals tested: n = 16 for wt, n = 11 APPswe, n = 14 for mGluR5−/− and n = 14 for APPswe/mGluR5−/− mice. Data represent the mean ± SEM.
The * indicates statistically significant (p < 0.05) differences between mice groups as compared with wild-type mice.
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respectively (Figure 3B-D). Because APP was transgenically
(ectopically) overexpressed in APPswe/PS1ΔE9 mice, we
tested whether the reduction of Aβ following the genetic de-
letion of mGluR5 was associated with reduced APP expres-
sion in whole brain lysates derived from 12 month old wild
type and APPswe/PS1ΔE9 mice that either expressed or
lacked mGluR5. We found that the genetic deletion of
mGluR5 had no apparent effect on the transgenic APP
expression in double transgenic APPswe/PS1ΔE9 mice
(Figure 3E). Thus, the expression of mGluR5 appeared
to influence the cleavage of APP towards an amyloido-
genic pathway in the APPswe/PS1ΔE9 double trans-
genic mouse model, and mGluR5 deletion functions to
reduce both Aβ oligomer formation and plaque num-
ber in APPswe/PS1ΔE9 mice.
mGluR5 cell surface expression and InsP signaling in
APPswe/PS1ΔE9 mice
Aβ oligomers were previously reported to activate mGluR5
and promote mGluR5 clustering at synapses [18]. There-
fore, we examined whether the cell surface expression ofmGluR5 was altered in APPswe/PS1ΔE9 mice at 12 months
of age as compared to wild-type controls. Using coronal
brain slices from 12 month old wild type and APPswe/
PS1ΔE9 mice, we determined total mGluR5 expression, as
well as the plasma membrane expression for mGluR5 by
performing a cell surface biotinylation assay [32]. We
found that the cell surface expression of mGluR5 was in-
creased by 4.4 ± 0.7 fold in APPswe/PS1ΔE9 mice when
compared with wild-type mice, without a change in total
cellular expression of mGluR5 (Figure 4A and B). No
mGluR5 expression was observed in mGluR5−/− mouse
lines. The observed increase in mGluR5 cell surface ex-
pression suggested the possibility that mGluR5-dependent
cell signaling in APPswe/PS1ΔE9 was increased in vivo in
response to either glutamate or soluble Aβ oligomers.
Therefore, we tested whether InsP formation in cross
chopped (prisms) cortical brain slices derived from
12 month old wild-type and APPswe/PS1ΔE9 mice,
that either express or lack mGluR5 expression was al-
tered following treatment with the Group I mGluR
agonist DHPG (5 or 50 μM). We found that despite in-
creased mGluR5 cell surface expression in APPswe/
Figure 3 Aβ formation and plaque number is reduced in 12 month old APPswe/PS1ΔE9 mice following the genetic deletion of
mGluR5. Shown in (A) is the concentration of whole brain β amyloid oligomer (ng/mg protein) concentrations in 12 month old wild-type (wt)
and APPswe/PS1ΔE9 (APPswe) mice on either mGluR5+/+or mGluR5−/− genetic backgrounds. Data represents the mean ± SEM of four independent
experiments. The * indicates statistically significant (p < 0.05) differences between β amyloid oligomer concentrations in APPswe/PS1ΔE9 mouse brains
as compared with mice that do not express APPswe/PS1ΔE9. The ψ indicates statistically significant differences between β amyloid oligomer
concentrations in APPswe mice that express mGluR5 as compared to APPswe mice that lack mGluR5 expression. Also shown are representative
images of Aβ plaques in the cortex and hippocampus of 12 month old coronal brain slices from (B) APPsweand (C) APPswe/mGluR5−/− mice. Scale
bar is 900 μm. (D) The graph shows the number of plaques counted 8100 μm2 regions of interests in the cortex and hippocampus in coronal brain
slices from 12 month old APPswe and APPswe/mGluR5−/− mice. (E) Representative immunoblot and quantification of APP expression in wt and
APPSwe mice either expressing or lacking mGluR5 expression. Data represents the mean ± SEM of four independent experiments. The * indicates
statistically significant (p < 0.05) differences between APPswe expressing mGluR5 as are compared with APPswe lacking mGluR5 expression.
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InsP formation was not significantly different between
cortical prisms derived from either 12 month old wild-
type or APPswe/PS1ΔE9 mice (Figure 4C). However, an
increase in DHPG-stimulated InsP formation was ob-
served in APPswe/PS1ΔE9 mice lacking mGluR5, when
compared with wild-type mGluR5 knockout tissue, sug-
gesting that mGluR1 may compensate to some extent for
the loss of mGluR5 expression in the APPswe/PS1ΔE9
mice (Figure 3C). This might be the consequence of com-
pensatory mGluR1 expression in the APPswe/PS1ΔE9
mice [33].
FMRP expression is increased in APPswe/PS1ΔE9 mice
The activity and expression of FMRP, a RNA binding
protein involved in the regulation of APP translation
and processing, is modulated by mGluR5 [23,24]. Thus,
it is possible that mGluR5-activated cell signaling path-
ways, acting independent of agonist-mediated G proteinsignaling pathways, might bias mGluR5 signaling, as a
consequence of increased cell surface mGluR5 expres-
sion in APPswe/PS1ΔE9 mice, towards alternative signal
transduction pathways. Specifically, mGluR5 activation
not only modulates FMRP expression, but regulates FMRP
activity via the activation of mTOR [34]. Therefore, we ex-
amined whether p-mTOR (p-2481) phosphorylation was
increased in cortical brain tissue derived from wild-type
and APPswe/PS1ΔE9 mice that either express or lack
mGluR5 expression at 12 months of age. We found an
increase in p-mTOR staining in cortical sections de-
rived from APPswe/PS1ΔE9 mice that express mGluR5
when compared to all other genotypes (Figure 5A and
C) with no significant alterations in total mTOR stain-
ing observed between phenotypes (Figure 5B and D).
This corresponded to an 82 ± 17% increase in in situ
mTOR phosphorylation in cortical tissue slices from
APPswe/PS1ΔE9 mice at 12 months of age, as com-
pared with wild-type mice. In addition, we examined
Figure 4 Increased mGluR5 cell surface expression does not
alter InsP signaling in 12 month old APPswe/PS1ΔE9 mice.
(A) Shown is a representative immunoblot showing increased cell
surface expression, but not total cellular expression, of mGluR5 in brain
lysates derived from 12 month wild-type (wt) versus APPswe/PS1ΔE9
(APPswe) mice. Loss of mGluR5 expression following mGluR5
knockout is also shown for both mouse lines. (B) Graph shows
the quantification of the relative cell surface expression of mGluR5
in wt versus APPswe mice at 12 months of age. Data represents
the mean ± SEM of four independent experiments. The * indicates
statistically significant (P < 0.05) differences between in APPswe mice,
as compared to wt mice (P < 0.05). Shown in (C) is mGluR1/5-stimu-
lated InsP formation in response to either 5 μM or 50 μM DHPG for 15
min at 37°C in cortical prisms derived from either wt or APPswe mice,
that either express mGluR5 (+/+) or do not express mGluR5 (−/−). The
data represents the means ± SEM of four independent experiments,
and is expressed as percentage of the maximum response to 50 μM
DHPG-stimulated InsP formation in wild type slices. The * indicates
statistically significant (P < 0.05) differences in InsP formation following
treatment of tissue with either 5 or 50 μm DHPG concentrations
between cortical prisms derived from wt and APPswe mice and
cortical prisms derived from wt and APPswe/PS1ΔE9 mice that do
not express mGluR5. # Indicates statistically significant (P < 0.05)
differences in InsP formation following treatment of tissue with
either 5 and 50 μm DHPG concentrations between cortical prisms
derived from wt and APPswe that do not express mGluR5.
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in brain lysates derived from APPswe/PS1ΔE9 mice at
12 months of age and found that mTOR phosphorylation
was significantly increased by 22 ± 0.8%, as compared with
wild-type mice (Figure 5E and F).
Because both mGluR5 and mTOR activation influence
FMRP expression and activity, we tested whether FMRP
expression was altered in APPswe/PS1ΔE9 mice as com-
pared to wild-type mice. We found that FMRP expres-
sion was increased by 2.6 ± 0.6 fold in APPswe/PS1ΔE9
mice at 12 months of age, as compared to wild-type
mice (Figure 6A and B). Genetic deletion of mGluR5 sig-
nificantly reduced FMRP expression APPswe/PS1ΔE9
mice (Figure 6A and B). These observations suggest that
mGluR5 activation by Aβ oligomers promotes a positive
feedback loop promoting APP cleavage of AD toward
the amyloidogenic pathway in APPswe/PS1ΔE9 mice.
Discussion
The neurodegeneration characteristic of AD is associ-
ated with Aβ oligomers, which bind to neuronal synap-
ses to both alter synaptic signaling and promote synaptic
loss [35-37]. We show here, that mGluR5 signaling in
double transgenic APPswe/PS1ΔE9 mice not only con-
tributes to impaired spatial learning, but also increases
the formation of Aβ oligomers and β-amyloid plaques
which are the pathophysiological hallmarks of AD. In
addition, spatial learning deficits observed in double
transgenic APPswe/PS1ΔE9 mice are ameliorated by the
genetic deletion of mGluR5, which is consistent with the
Figure 5 p-mTOR activation in APPswe/PS1ΔE9 mice. Shown is immunohistochemical staining (A) for p-mTOR (pSer2481) staining in
representative fields of coronal tissue from wild type (wt), APPswe/PS1ΔE9 (APPswe), mGluR5−/− and APPswe/mGluR5−/− mice at 12 months
of age (B) and mTOR (pSer2481) staining in representative fields of coronal tissue from wt, APPswe, mGluR5−/−, and APPswe/mGluR5−/− mice
at 12 months of age. Scale bar = 100 μm. (C) The graph shows the number of p-mTOR positive cells counted 8100 μm2 regions of interests
in the cortex of 12 month old from wt, APPswe, mGluR5−/−, and APPswe/mGluR5−/− mice. Data represents the mean ± SEM of four independent
experiments. The * indicates statistically significant (p < 0.05) differences between wt and APPswe mice. (D) The graph shows the number of
total mTOR positive cells counted 8100 μm2 regions of interests in the cortex of 12 month old wt, APPswe, mGluR5−/−, and APPswe/mGluR5−/−. Data
represents the mean ± SEM of four independent experiments. Shown in (E) is a representative immunoblot for p-mTOR (pSer2481), total mTOR
and actin in lysates derived from cortical brain section from wt and APPswe mice that either express mGluR5 (+/+) or do not express mGluR5
(−/−). (F) Shown in the graph is the analysis of the mean ± SD for four independent experiments for mTOR phosphorylation in wt and APPswe
mouse cellular lysates that either express mGluR5 or do not express mGluR5. The * indicates statistically significant (P < 0.05) differences
between mTOR phosphorylations in APPswe as compared to wt mice.
Hamilton et al. Molecular Brain 2014, 7:40 Page 7 of 12
http://www.molecularbrain.com/content/7/1/40recent report that pharmacological blockade of mGluR5
with the mGluR5-specific antagonist MTEP improved
behavioural deficits in APPswe/PS1ΔE9 mice [17]. How-
ever, we unexpectedly found that mGluR5 signaling may
also contribute to the etiology of AD pathology by pro-
moting the formation of Aβ oligomers in APPswe/
PS1ΔE9 mice, which are considered to be important me-
diators of neurotoxic signaling at glutamatergic synapses.
It is also now recognized that mGluR5 functions as areceptor for both Aβ oligomers [17-19], and PrPc to medi-
ate Aβ oligomer-dependent release of Ca2+ from intracel-
lular stores, an event which may be neurotoxic [17]. Aβ
oligomers also mediate clustering of mGluR5 at synapses,
the consequence of which may contribute to the func-
tional impairment of synaptic activity [18]. Our data sug-
gest that Aβ oligomer interactions with mGluR5 may also
function to accelerate Aβ production via the mGluR5-
and FMRP-dependent activation of the amyloidogenic
Figure 6 Increased FMRP protein expression in APPswe/PS1ΔE9
mice. (A) Shown is a representative immunoblot for FMRP expression
in wild-type (wt) and APPswe/PS1ΔE9 (APPswe) mice on either
mGluR5+/+or mGluR5−/− genetic backgrounds. The data shown in
(B) represent the mean ± SD of four independent experiments
demonstrating increase FMRP protein expression in APPswe mice
that is lost following the genetic deletion of mGluR5. The * indicates a
statistically (P 0.05) significant differences in FMRP expression between
APPswe/PS1ΔE9 mice and wild-type mice.
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APPswe/PS1ΔE9 mouse model of AD, Aβ oligomers initi-
ate a neurodegenerative positive feedback loop that in-
creases mGluR5 activity leading to an increase in Aβ
oligomer formation that culminates in AD-like pathology
and impaired spatial learning. The genetic deletion of
mGluR5 in APPswe/PS1ΔE9 mice effectively severs this
feedback loop, reducing Aβ oligomer and plaque forma-
tion resulting in improved cognitive performance in
APPswe/PS1ΔE9 mice.
We found that there was no change in swim speed the
mouse groups tested suggesting that altered locomotion
or anxiety did not account for changes in MWM per-
formance, in the data presented to illustrate learning we
showed both path length and escape latency. While an
expedient escape latency could be attributed to hyper-
activity, the fact that there was no difference in swim
speed, and no significant difference in path length, this
indicates that the mGluR5 knockout mice learn the task,
as well as the wild type animals. We also found no
changes in anxiety behaviour in the elevated plus maze.
Our results were completely consistent with recent data
showing mGluR5 antagonism improved APPswe/PS1ΔE9mouse behaviour in MWM [17]. The previously mGluR5
knockout deficit in the MWM reported by Lu et al. [38]
was in mice of undocumented age and did not involve the
comparison of aged mice.
The activation of mGluR5 triggers the mRNA binding
protein FMRP to release APP repression, promoting its
translation [20,23,24]. In fragile X syndrome, this inter-
action leads to increased cleavage of APP [19,22], sug-
gesting that similar processes may be occurring in AD
brain. APP cleavage occurs via a non-amyloidogenic
pathway and an amyloidogenic pathway, which is con-
sidered to function as an “overflow” pathway activated
as a consequence of excessive APP production resulting
in increased APP cleavage and the formation of toxic Aβ
oligomers [3,39]. Thus, Aβ mediated activation of mGluR5
may result in both increased FMRP expression and APP
processing. We propose that the observed increase in
FMRP protein expression in APPswe/PS1ΔE9 mice repre-
sents a compensatory mechanism that is engaged to po-
tentially reduce ectopic/transgenic translational control of
APP translation. However, since mTOR activity is also in-
creased in APPswe/PS1ΔE9 mice increased FMRP expres-
sion levels may be ineffective in reducing APP translation.
There is evidence that G protein-coupled receptors regu-
late γ-secretase activity in a β-arrestin-dependent manner
to alter Aβ production [40]. However, the link between
mGluR5 signaling and β-arrestin activation is contro-
versial [41]. As a consequence, Aβ oligomer-stimulated
mGluR5 activity may function to promote the cleavage
of APP via the amyloidogenic pathway.
The degeneration of glutamatergic synapses is associ-
ated with disrupted neuronal signaling and synaptic loss
has traditionally been associated with alterations in iono-
tropic NMDA and AMPA receptor signaling [3,42-44].
However, the pharmacological blockade of the NMDAR
has not met with success for the treatment of neurode-
generative disease [38]. The recent identification of mGluR5
as a potential disease modifier in AD provides a potential
for novel mGluR5 antagonist-based pharmacological inter-
ventions for the treatment of AD. mGluR5 blockade was ef-
fective in improving spatial learning in APPswe/PS1ΔE9
mice and we reported that mutant huntingtin protein aggre-
gates are significantly reduced in a mutant Huntingtin
knock-in model that lacks mGluR5 expression [12]. Taken
together these observations suggest a generalized potential
for mGluR5 antagonists in the treatment of neurodegenera-
tive disease.
In summary, we show that mGluR5, which functions
as a membrane bound receptor scaffolds for both PrPc
and Aβ oligomers [17-19], functions to transduce Aβ
oligomer-mediated signals as alterations in intracellular
Ca2+ signaling, as well as FMRP/Aβ mediated patho-
logical signaling in the APPswe/PS1ΔE9 mouse model
of AD. Although these studies provide additional evidence
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to antagonize AD progression, additional pharmacological
studies will be required in non-human primates to validate




Sulfo-NHS-SS-biotin and Neutravidin were purchased
from Thermo Scientific (Waltham, MA, USA. Mouse anti-
FMRP antibody was purchased from Abcam (Cambridge,
UK). DHPG was purchased from Tocris Bioscience (Bristol,
UK). Myo-[3H]-inositol was purchased from Perkin Elmer
(Waltham, MA, USA). Dowex I-X8 resin, rabbit anti APP
antibody, rabbit anti-phospho mTOR (pSer2481) antibody
and rabbit anti-mTOR antibody were purchased from
Sigma-Aldrich (St. Louis, MO, USA).Goat anti-rabbit sec-
ondary antibody was purchased from BioRad (Hercules,
CA, USA). Aggregated Aβ human ELISA kit and rabbit
Aβ peptide antibody were purchased from Invitrogen
(Carlsbad, CA, USA). Rabbit anti-mGluR5 was purchased
from Millipore (Billerica, MA, USA). Finally Vector Elite
ABC kit rabbit and mouse, and Vector SG substrate was
purchased from Vector laboratories. All other biochemical
reagents were purchased from Sigma-Aldrich (St. Louis,
MO, USA).
Mouse model
STOCK B6C3-Tg (APPswe/PSEN1ΔE9)85Dbo/J mice that
carry the human APP with Swedish mutation and the Del-
taE9 mutation of the human presenilin 1 gene and mGluR5
knockout mice B6;129-Grm5tm1Rod/J (mGluR5−/−) were
purchased from Jackson Laboratory (Bar Harbor, ME)
[38,45]. APPswe/PS1ΔE9/mGluR5−/− mice were gener-
ated by crossing APPswe/PS1ΔE9 mice with a C57/Bl6
background, with mGluR5−/− C57/Bl6 females. Off-
spring were tail snipped and genotyped using PCR with
primers specific for the APP sequence and primers
specific for mGluR5. The following genotypes were
generated and used for experiments APPswe/PS1ΔE9/
mGluR5−/−, APPswe/PS1ΔE9/mGluR5+/+, APPswe/PS1ΔE9
−/−/mGluR5−/− and wild type littermate controls. Animals
were housed in an animal care facility in cages of 2 or more
animals, and were maintained on a 12 hour light/12 hour
dark cycle at 24°C. Mice received food and water ad libi-
tum. Mice were aged to 9 and 12 months before use in a
battery of behavioural and biochemical experiments. All
animal experiments were conducted in accordance with
the University of Western Ontario animal care committee.
Morris water maze
Any Maze software connected to a video camera was
used to track the activity of animals within the maze.
The maze was a white opaque plastic pool (120 cm indiameter), filled with water and maintained at 25°C to
prevent hypothermia. A clear escape platform (10 cm
diameter) was placed 25 cm from the perimeter, hidden
1 cm beneath the surface of the water. Visual cues were
placed on the walls in the room with the maze. Acquisi-
tion phase (day 1–4): Mice were trained over 4 consecu-
tive days, with 4 trials per day with 15 min intervals
between trials. Mice were randomly started from 4 equally
spaced points around the pool, across each of the 4 daily
trials. Animals were given 90 s to find the escape platform,
if they failed to do so they were guided to the platform
where they remained for 30 s, before being returned to
their home cage. Swim speed and escape latency were re-
corded and statistical analysis performed using Graph Pad
Prism. Probe trial (day 5): the probe trial is performed to
assess spatial memory. This is a singular 60 s trial, in
which the platform is removed and mice are allowed to
swim freely in the pool. Time spent in the target quadrant
was recorded and statistical analysis performed using
Graph Pad Prism software.
Open field
VersaMax animal activity monitors (AccuScan Instruments
Inc, Columbus, OH, USA) were used to measure loco-
motor activity. Experiments were performed during the
light cycle of the mice. Mice were allowed to explore open
field boxes (20 × 20 cm Plexi-glass boxes) for 120 min dur-
ing which time movement was measured at 5 min intervals
using beam breaks converted to cm. Measurements of total
distance travelled, center time and number of rearings were
calculated and statistical analysis performed using Graph
Pad Prism software.
Elevated plus maze
Mice were individually placed in one of the enclosed
arms of a plus-maze and the behavior of the animals was
recorded over a 5 min period by a ceiling-mounted video
camera. The amount of time spent in each of the arms,
the number of arm entries (an arm entry was defined as
all four of the paws being placed in an arm of the plus-
maze). The elevated plus-maze had two arms enclosed
by 21 cm high walls; whereas the remaining two arms
were open (arms were 24.8 cm long × 7.7 cm wide). The
maze was situated in a dimly lit room, such that the closed
arms were darkened, whereas open arms were somewhat
illuminated. All behavioural experiments were blinded.
Determination of β amyloid oligomer concentration by
sandwich ELISA
Brains were dissected into right and left hemisphere, with
one hemisphere used to analyse oligomeric Aβ. Quantifica-
tion of Aβ oligomers, in 12 month old fresh mouse brains,
was performed using a sandwich ELISA kit (KHB3491,
Invitrogen) according to manufacturer’s instructions.
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PS1ΔE9/mGluR5+/+, APPswe/PS1ΔE9−/−/mGluR5−/− mouse
brains were homogenized in Tris Buffered Saline (25 mM
Tris–HCl, pH 7.4; 150 mM NaCl) supplemented with prote-
ase inhibitor cocktail (1 mM AEBSF, and10 μg/ml aprotinin
of both leupeptin). Brain homogenates were centrifuged at
100,000 × g at 4°C for 1 hour. The supernatant was then di-
luted 1:10 before carrying out the ELISA, which was per-
formed in triplicate, measuring only Aβ oligomers, as
detailed in the manufacturer's protocol. Protein was quan-
tified using the Bradford protein assay (BioRad). The final
Aβ values were determined following normalization to
total protein levels.
β amyloid immunohistochemistry
Brains were dissected into left and right hemisphere,
with one hemisphere used for histology. Brains were cor-
onally sectioned to include both the cortex and hippocam-
pus. Immunohistochemistry was performed on 40 μm free
floating sections using a peroxidase based immunostaining
protocol. In brief, endogenous peroxidase activity was
quenched using 0.1% hydrogen peroxide, after which the
membranes were permeabilized using 1% triton X100 in
TBS. Non-specific binding was blocked using 1.5% normal
goat serum, followed by incubation in primary antibody
for Aβ (1:200, rabbit polyclonal, Invitrogen) overnight at
4°C. Sections were washed in 1xTBS, and then incubated
in secondary antibody (biotinylated goat anti-rabbit, 1:400,
Vector Elite ABC kit rabbit, Vector Laboratories) for
90 min at 4°C. Finally sections were incubated in an
avidin biotin enzyme reagent (Vector Elite ABC kit
rabbit, Vector Laboratories). Immunostaining was visua-
lised using a chromogen (Vector SG substrate, Vector La-
boratories). Sections were mounted on slides and visualized
using a Zeiss LSM-510 META multiphoton laser scanning
microscope with a Zeiss 10× lens, representative 900 μm ×
900 μm areas of cortex (4 regions of interest) and hippo-
campus (2 regions of interest) were imaged for analysis.
The number of Aβ positive puncta per image was counted
using the cell counter tool in Image J (NIH, USA).
Cell surface biotinylation
Cell surface biotinylation was performed as previously de-
scribed11. 350 μm coronal brain slices from wild-type,
APPswe/PS1ΔE9/mGluR5−/−, APPswe/PS1ΔE9/mGluR5+/+,
APPswe/PS1ΔE9−/−/mGluR5−/−mice were prepared using a
vibratome system (Leica). Slices were recovered in KREBS
buffer (127 mM NaCl, 2 mM KCl, 10 mM glucose, 1.2 mM
KH2PO4, 26 mM NaH2CO3, 1 mM MgSO4, 1 mM CaCl2,
pH 7.4) continuously gassed with 95%O2/5%CO2 for 30 min
at 37°C. Slices were transferred to tubes and biotinylated for
1 hr in 1.5 mg/ml sulfo-NHS-SS-biotin (Thermo Scientific)
for 1 h on ice. Slices were washed and biotinylation
quenched with 100 μM glycine in HBSS for 30 min on ice.Following washes in HBSS, tissue was lysed in RIPA buffer
(0.15 M NaCl, 0.05 M Tris–HCl, pH 7.2, 0.05 M EDTA,
1% Nonidet P40, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS) containing protease inhibitors (1 mM
AEBSF and 10 μg/ml of both leupeptin and aprotinin), ly-
sates were then polytroned until homogenous. Biotinylated
proteins were then precipitated on NeutrAvidin beads
using equivalent amounts of cellular protein for each sam-
ple. Biotinylated proteins were subjected to SDS-PAGE
and immunoblotted with Rabbit polyclonal mGluR5 anti-
body (1:1000, dilution), as described below.
Immunoblotting
Acute brain slices prepared, as described above, and re-
covered for 90 min at 37°C in KREBS continuously gassed
with 95%O2/5%CO2. Slices were then transferred to tubes,
gassed with 95%O2/5%CO2 before being capped tightly
and left to further recover at 37°C for 30 min. Slices were
flash frozen with 95% ethanol in a bath of dry ice and
lysed in RIPA buffer. 100 μg of total cellular protein for
each sample were subjected to SDS-PAGE, followed by
electroblotting onto nitrocellulose membranes. Membranes
were blocked with 10% milk in wash buffer (150 mM NaCl,
10 mM Tris–HCl, pH 7.0, and 0.05% Tween 20) for 1 h
and then incubated with rabbit anti-APP (1:4000), rabbit
anti-p-mTOR (pSer2481, 1:1000), rabbit anti-mTOR
(1:1000), mouse anti-FMRP (1:1000) or rabbit anti-actin
(1:10000) antibodies in wash buffer containing 3% milk
overnight. Membranes were rinsed three times with wash
buffer and then incubated with secondary horseradish
peroxidase-conjugated goat anti-rabbit or anti-mouse IgG
diluted 1:10000 in wash buffer containing 3% skim milk
for 1 h.
Inositol phosphate formation assay
[3H]Inositol phosphate formation in cortical slices
was performed, as previously described11. Dissected cortices
from age-matched wild-type, APPswe/PS1ΔE9/mGluR5−/−,
APPswe/PS1ΔE9/mGluR5+/+, APPswe/PS1ΔE9−/−/mGluR5−/−
mouse brains were cross-chopped using a McIlwain tissue
chopper. The cortical prisms were recovered by incubation
in KREBS buffer after being gassed with 95%O2/5%CO2 in
a shaking water bath at 37°C for 30 min. 40 μl of gravity-
packed prisms were transferred in duplicate to tubes,
gassed, and incubated with 1 μCi/ml myo-[3H]inositol
in a shaking bath at 37°C for 90 min. The prisms were
gassed again and incubated in a shaking water bath at
37°C for 15 min in 10 mM LiCl followed by stimula-
tion with 5 μM or 50 μM DHPG for 20 min. The reaction
was stopped by adding 900 μl of a 2:1 mix of chloroform:
methanol incubated for 15 min at room temperature,
followed by adding 300 μl of chloroform. The total [3H]
inositol incorporated into slices was determined by
counting the radioactivity present in the hydrophobic
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(formate form) 200–400 mesh anion exchange resin in col-
umns. Columns were washed three times with water
followed by 2 washes with 60 mM ammonium formate.
Samples were eluted with 200 mM ammonium formate
and 0.1 M formic acid into scintillation vials containing
scintillation fluid. [3H]Inositol phosphate formation was
determined by liquid scintillation using a Beckman LS
6500 scintillation system.
p-TOR and mTOR immunohistochemistry
Brains were coronally sectioned to include both the cortex
and hippocampus. Immunohistochemistry was performed
on 40 μm free floating sections using a peroxidase based
immunostaining protocol. In brief; endogenous peroxidase
activity was quenched using 0.1% hydrogen peroxide, after
which the membranes were permeabilized using 1% triton
X100 in TBS. Non-specific binding was blocked using
1.5% normal goat serum, followed by incubation in pri-
mary antibody for p-mTOR (1:200 diltion, rabbit poly-
clonal pSer2481 antibody) and mTOR (1:200, rabbit
polyclonal antibody) overnight at 4°C. Sections were
washed in 1xTBS, and then incubated in secondary anti-
body (biotinylated goat anti-rabbit, 1:400, Vector Elite
ABC kit rabbit, Vector Laboratories) for 90 min at 4°C.
Finally sections were incubated in an avidin biotin en-
zyme reagent (Vector Elite ABC kit rabbit, Vector Labora-
tories). Immunostaining was visualised using a chromogen
(Vector SG substrate, Vector Laboratories). Sections were
mounted on slides and visualized using a Zeiss LSM-510
META multiphoton laser scanning microscope with a
Zeiss 10× lens, representative 900 μm × 900 μm areas
of cortex (4 regions of interest) and hippocampus (2 re-
gions of interest) were imaged for analysis. The number of
p-mTOR and mTOR positive cells per image was counted
using the cell counter tool in Image J (NIH, USA).
Data analysis
Means ± SEM are shown for the number of independent
experiments indicated in Figure Legends. GraphPad Prism
software was used to analyze data for statistical signifi-
cance and for curve fitting. Statistical significance was de-
termined by analysis of variance (ANOVA) followed by
post-hoc testing.
Additional file
Additional file 1: Figure S1. Time spent in each of the quadrants of
the Morris Water Maze for each of the mouse genotypes tested and 12
months of age.
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